Overview

A Crossover Study in the Treatment of Patients With COPD

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID], and to Compare the preference/compliance of BID nebulization to QID use of MDI
Phase:
Phase 3
Details
Lead Sponsor:
Dey
Treatments:
Albuterol
Bromides
Formoterol Fumarate
Ipratropium